$0.21 EPS Expected for Meridian Bioscience, Inc. (VIVO) This Quarter

Analysts expect that Meridian Bioscience, Inc. (NASDAQ:VIVO) will report earnings of $0.21 per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Meridian Bioscience’s earnings. The lowest EPS estimate is $0.20 and the highest is $0.22. Meridian Bioscience also posted earnings of $0.21 per share in the same quarter last year. The company is expected to issue its next earnings report on Thursday, April 25th.

On average, analysts expect that Meridian Bioscience will report full-year earnings of $0.76 per share for the current year, with EPS estimates ranging from $0.74 to $0.77. For the next fiscal year, analysts anticipate that the business will post earnings of $0.78 per share, with EPS estimates ranging from $0.74 to $0.81. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover Meridian Bioscience.

Meridian Bioscience (NASDAQ:VIVO) last announced its quarterly earnings results on Thursday, January 24th. The company reported $0.20 EPS for the quarter, beating the Zacks’ consensus estimate of $0.18 by $0.02. Meridian Bioscience had a net margin of 12.06% and a return on equity of 19.27%. The company had revenue of $51.48 million for the quarter, compared to analysts’ expectations of $51.50 million. During the same period in the prior year, the company posted $0.15 EPS. Meridian Bioscience’s revenue was down 1.5% compared to the same quarter last year.

Several analysts have issued reports on VIVO shares. ValuEngine upgraded shares of Meridian Bioscience from a “hold” rating to a “buy” rating in a research note on Monday, October 29th. BidaskClub upgraded shares of Meridian Bioscience from a “hold” rating to a “buy” rating in a research note on Wednesday, October 24th. Finally, Zacks Investment Research cut shares of Meridian Bioscience from a “buy” rating to a “hold” rating and set a $19.00 target price on the stock. in a research note on Saturday, January 19th.

NASDAQ VIVO traded up $0.10 on Monday, hitting $16.29. The stock had a trading volume of 420,300 shares, compared to its average volume of 352,258. Meridian Bioscience has a 52-week low of $13.53 and a 52-week high of $19.84. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.75 and a quick ratio of 4.02. The stock has a market capitalization of $686.50 million, a PE ratio of 22.01 and a beta of 0.41.

The company also recently announced a quarterly dividend, which will be paid on Thursday, February 14th. Shareholders of record on Monday, February 4th will be paid a $0.125 dividend. This represents a $0.50 annualized dividend and a yield of 3.07%. The ex-dividend date is Friday, February 1st. Meridian Bioscience’s dividend payout ratio is presently 67.57%.

In other Meridian Bioscience news, EVP Lawrence Baldini sold 35,101 shares of the stock in a transaction that occurred on Tuesday, November 13th. The shares were sold at an average price of $19.41, for a total value of $681,310.41. Following the sale, the executive vice president now directly owns 76,129 shares in the company, valued at approximately $1,477,663.89. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 2.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of VIVO. Dimensional Fund Advisors LP increased its holdings in shares of Meridian Bioscience by 0.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,828,334 shares of the company’s stock worth $29,071,000 after buying an additional 9,714 shares during the last quarter. Macquarie Group Ltd. bought a new position in shares of Meridian Bioscience in the 2nd quarter worth $119,000. Bank of New York Mellon Corp increased its holdings in shares of Meridian Bioscience by 1.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 811,847 shares of the company’s stock worth $12,908,000 after buying an additional 13,937 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Meridian Bioscience by 1.8% in the 2nd quarter. Northern Trust Corp now owns 559,989 shares of the company’s stock worth $8,904,000 after buying an additional 10,119 shares during the last quarter. Finally, State of Alaska Department of Revenue increased its holdings in shares of Meridian Bioscience by 40.1% in the 3rd quarter. State of Alaska Department of Revenue now owns 19,248 shares of the company’s stock worth $285,000 after buying an additional 5,505 shares during the last quarter. Institutional investors and hedge funds own 92.40% of the company’s stock.

About Meridian Bioscience

Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.

Featured Article: Marijuana Stocks Investing Considerations

Get a free copy of the Zacks research report on Meridian Bioscience (VIVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply